No abstract

The results of an experimental study of the electroluminescent device made of ITO/CuI/2,6-di-tert.-butyl-4-(2,5-diphenyl-3,4-dihydro-2H-pyrazol-3-yl)- phenol (HPhP)/3,6-Di(9-carbazolyl)-9-(2-ethylhexyl) carbazole (TCz1)/Ca:Al with efficacy up to 10.63 cd/A are presented. HPhP provides blue emission with a peak wavelength at 445 nm. The layer of TCz1 acts as an electron-transporting layer. In the framework of density functional theory (DFT) approach the geometry configuration and energy levels of HPhP are found being in a good agreement with spectral and cyclic voltammogram data. © 2011 Elsevier B.V

Neuroinflammation is an integral part of epilepsy pathogenesis and other convulsive conditions, and non-steroidal anti-inflammatory drugs (NSAIDs) present a potent tool for the contemporary search and design of novel anticonvulsants. In the present paper, evaluation of the anticonvulsant activity of the potential NSAID dual COX-2/5-LOX inhibitor darbufelone methanesulfonate using an scPTZ model in mice in dose 100 mg/kg is reported. Darbufelone possesses anticonvulsant properties in the scPTZ model and presents interest for in-depth studies as a possible anticonvulsant multi-target agent with anti-inflammatory activity. The series of 4-thiazolidinone derivatives have been synthesized following the analogue-based drug design and hybrid-pharmacophore approach using a darbufelone matrix. The synthesized derivatives showed a significant protection level for animals in the scPTZ model and are promising compounds for the design of potential anticonvulsants with satisfactory drug-like parameters.

No abstract

No abstract